Acute decompensated heart failure (ADHF) is a major cause of hospitalizations in older adults, lead-ing to high mortality, morbidity, and healthcare costs. To address the persistent poor outcomes in ADHF, novel device-based approaches targeting specific patho-physiological mechanisms are urgently needed. The recently introduced DRI2P2S classification categorizes these innovative therapies based on their mechanisms. Devices include dilators (increasing venous capaci-tance), removers (directly removing sodium and water), inotropes (enhancing left ventricular contractil-ity), interstitials (accelerating lymph removal), pushers (increasing renal arterial pressure), pullers (decreasing renal venous pressure), and selective drippers (selective intrarenal drug infusion). Some are tailored for chronic HF, while others focus on the acute setting. Most devi-ces are in early development, necessitating further research to understand mechanisms, assess clinical effectiveness, and ensure safety before routine use in ADHF management. Exploring these innovative device-based strategies may lead to improved outcomes and revolutionize HF treatment in the future. (Curr Probl Cardiol 2023;48:102023.)
Innovative Device-Based Strategies for Managing Acute Decompensated Heart Failure
Caglioni S.;
2023
Abstract
Acute decompensated heart failure (ADHF) is a major cause of hospitalizations in older adults, lead-ing to high mortality, morbidity, and healthcare costs. To address the persistent poor outcomes in ADHF, novel device-based approaches targeting specific patho-physiological mechanisms are urgently needed. The recently introduced DRI2P2S classification categorizes these innovative therapies based on their mechanisms. Devices include dilators (increasing venous capaci-tance), removers (directly removing sodium and water), inotropes (enhancing left ventricular contractil-ity), interstitials (accelerating lymph removal), pushers (increasing renal arterial pressure), pullers (decreasing renal venous pressure), and selective drippers (selective intrarenal drug infusion). Some are tailored for chronic HF, while others focus on the acute setting. Most devi-ces are in early development, necessitating further research to understand mechanisms, assess clinical effectiveness, and ensure safety before routine use in ADHF management. Exploring these innovative device-based strategies may lead to improved outcomes and revolutionize HF treatment in the future. (Curr Probl Cardiol 2023;48:102023.)I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
